Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer.

Liu, Jia; Zhu, Tienian; Liu, Jiankun; Cui, Yujie; Yang, Shifang; Zhao, Ruijing

Liu, Jia; Zhu, Tienian; Liu, Jiankun; Cui, Yujie; Yang, Shifang; Zhao, Ruijing.

Afiliação

Liu J; Department of Oncology, Hebei Medical University, Shijiazhuang 050017, China.
Zhu T; Department of Hematology, Affiliated Hospital of Hebei University, Baoding 071000, China.
Liu J; Department of Oncology, Hebei Medical University, Shijiazhuang 050017, China.
Cui Y; Department of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang 050082, China.
Yang S; Department of Oncology, Hebei Medical University, Shijiazhuang 050017, China.
Zhao R; Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, China.

Acta Biochim Biophys Sin (Shanghai) ; 55(8): 1247-1256, 2023 Aug 10.

Article em En | MEDLINE | ID: mdl-37559457

Assuntos

Antineoplásicos; Neoplasias da Mama; Neoplasias de Mama Triplo Negativas; Animais; Camundongos; Humanos; Feminino; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Neoplasias de Mama Triplo Negativas/genética; Neoplasias de Mama Triplo Negativas/metabolismo; Camundongos Nus; Linhagem Celular Tumoral; Doxorrubicina/farmacologia; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Apoptose; Neoplasias da Mama/tratamento farmacológico

Palavras-chave

TRAIL; apoptosis; death receptor; doxorubicin; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias de Mama Triplo Negativas / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google